Explore the Agenda
7:30 am Check In & Refreshments
8:20 am Chair’s Opening Remarks
Defining the Future of Induced Proximity & Translating Scientific Innovation Into Clinically Transformative Therapies for Patients with Unmet Medical Need
8:30 am Degradation Delivered – What the First TPD Approval Means for the Future of the Field
- Significance of the first approved targeted protein degrader
- What the future of TPD holds beyond oncology; other targets to explore and consider
- High-level overview of what is next for Arvinas, it’s pipeline and targets
9:00 am Panel Discussion: Navigating the Evolving Induced Proximity Landscape: Trends, Opportunities & Global Impact
- Examining recent advances across degrader and non-degrader modalities, highlighting how new discoveries are moving the field beyond oncology
- Assessing the influence of global markets, including China, on drug development, the clinical landscape and strategic collaborations in induced proximity therapeutics
- Identifying emerging opportunities, bottlenecks, and the next frontiers in translating platform innovations into clinically relevant therapies
9:30 am Beyond Degraders: Are We Asking the Wrong Questions in Induced Proximity?
- Scalable discovery of molecular glue degraders beyond CRBN
- Protein relocalization through proximity using RELOTACs
- Restoring and reprogramming biology
10:00 am Sponsorship Opportunity Available!
10:30 am Morning Break & Speed Networking
This is your opportunity to connect with your TPD & Induced Proximity peers to exchange business cards, discuss your research and forge the future of drug development
Track A: Discovery
Expanding the Ligase Toolbox & Pursuing Novel Ligases to Overcome the Limitations of Cereblon & Expand Therapeutic Scope
11:30 am Expanding the Degrader Toolbox for Neuro Applications
Chief Executive Officer, Trimtech Therapeutics
- Differentiation of TRIMTECH’s TRIM21 platform and applicability to neurodegeneration
- Data supporting selective and potent degradation of toxic protein aggregates
- Bifunctional and molecular glue strategies for these target classes
12:00 pm High-Throughput Proteomics Powering Molecular Glue Degrader Discovery
Chief Scientific Officer, NEOsphere Biotechnologies GmbH
- Large-scale proteomic screening of >5,000 compounds identified and validated 250+ molecular glue degrader targets, among them CDK4
- Mapping chemical structures to degradation and interactomics profiles provides a high-resolution, proteome-wide view of target spectrum, compound-induced protein regulation, and protein-protein interactions
- These datasets fuel proteomics-driven AI/ML, enabling rational molecular glues design and selectivity optimization
12:30 pm A Novel TPD Platform Leveraging a New E3 Ligase to Minimize Hematologic Toxicity
Founder & Chief Executive Officer, Pin Therapeutics
- Introduction of a novel TPD platform with a differentiated profile based on a new E3 ligase
- Data highlighting efficient target degradation with reduced hematologic off-target effects
- Insights into strategies to mitigate toxicity risk in future TPD development
1:00 pm Lunch Break & Networking Time
Building Integrated Discovery Platforms to Enable Induced Proximity Innovation through Advanced Chemistry, Assays & Screening Technologies
2:00 pm MOPED™ Molecular Proximity Enabled Detection : A Novel Platform for the Discovery of Molecular Glue
Senior Director, SK Life Science Labs
- MOPED is a high-throughput, multiplexed screening platform capable of identifying weak
- molecular glues
- It can identify compounds that induce a productive POI-E3 ternary complex
- The platform is adaptable for applications beyond TPD
2:30 pm Session Details to be Announced
- Sai Life Sciences
2:40 pm Discovery of Molecular Glues at Scale
Chief Scientific Officer, Serinus Biosciences
- ApoXY is a massively multiplexed platform to discover molecular glues. It enables high throughput screening of molecules against dozens of protein pairs simultaneously inside of eukaryotic cells
- ApoXY robustly detects weakly induced interactions that may be degrading or non-degrading, enabling discovery of molecular glues agnostic of therapeutic mechanism of action
- We are applying ApoXY to discover best-in-class and first-in-class molecular glues in oncology and immunology
3:10 pm Inducing the Selective Degradation of Cyclin D1 by Interfering with its Folding Pathway
Co-Founder & Chief Technology Officer, Sibylla Biotech srl
- Application of physics-based computational simulations to map the folding landscape of Cyclin D1 and identify ligandable pockets exposed along its folding pathway
- Discovery and optimization of small molecules that engage a folding intermediate of Cyclin D1, perturb its folding pathway, and induce selective degradation of the nascent protein
- In vitro and in vivo evidence supporting pharmacological targeting of the Cyclin D1 folding pathway as a novel therapeutic strategy
3:40 pm 3.40 Afternoon Break & Poster Session
Building Integrated Discovery Platforms to Enable Induced Proximity Innovation through Advanced Chemistry, Assays & Screening Technologies
4:30 pm Session Details to be Announced
- NanoTemper
5:00 pm Harnessing Sphingolipid Biology for Targeted Degradation of Soluble & Membrane Proteins
Co-Founder & Chief Scientific Officer, Transcera Inc.
- Building on fundamental discoveries in sphingolipid biology, Transcera develop a new modality for extracellular protein degradation that harness native ceramide trafficking pathways
- Transcera’s degraders work across multiple cell types in tissues throughout the body and have extended half-life for durable target depletion,
- Transcera discovered new degraders for immune-mediated disease and is advancing towards a clinical candidate
Track B: Pre-Clinical Development
Track C: Translational & Clinical Development